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ABSTRACT  
The reason of writing this research article on gastro retentive drug delivery systems was to gather the recent literature with special focus on various gastro retentive approaches 
that have recently become leading methodologies in the field of site-specific orally administered controlled release drug delivery. In order to identify with various physiological 
difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention. Afterwards, we have reviewed various gastro retentive approaches 
designed and developed until now, i.e. microspheres, microcapsules, floating gel beads, floating matrix tablets and in-situ gel, with advantages and limitations of gastro retentive 
drug delivery systems in detail. 
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INTRODUCTION 
Oral administration is the most convenient and preferred means of 
any  drug  delivery  to  the  systematic  circulation.  Oral  controlled 
release  drug  delivery  have  recently  been  of  increasing  interest  in 
pharmaceutical  field  to  achieve  improved  therapeutic  advantages, 
such  as  ease  of  dosing  administration,  patient  compliance  and 
flexibility  in  formulation.  Drugs  that  are  easily  absorbed  from 
gastrointestinal tract (GIT) and have short half-lives are eliminated 
quickly  from  the  systemic  circulation.  Frequent  dosing  of  these 
drugs is required to achieve suitable therapeutic activity. To avoid 
this limitation, the development of oral sustained-controlled release 
formulations  is  an  attempt  to  release  the  drug  slowly  into  the 
gastrointestinal  tract  (GIT)  and  maintain  an  effective  drug 
concentration in the systemic circulation for a long time. After oral 
administration,  such  a  drug  delivery  would  be  retained  in  the 
stomach and release the drug in a controlled manner, so that the drug 
could  be  supplied  continuously  to  its  absorption  sites  in  the 
gastrointestinal tract (GIT)
 1. 
Gastroretentive  drug  delivery  is  an  approach  to  prolong  gastric 
residence  time,  thereby  targeting  site-specific  drug  release  in  the 
upper  gastrointestinal  tract  (GIT)  for  local  or  systemic  effects. 
Gastroretentive dosage  forms can remain in the gastric region for 
long 
Periods and hence significantly prolong the gastric retention time 
(GRT) of drugs. 
Over  the  last  few  decades,  several  gastro  retentive  drug  delivery 
approaches being designed and developed, including 
  High-density   systems.  
  Floating systems.  
  1. Hydrodynamically balanced systems: HBS  
  2. Raft-forming systems.  
  3. Low-density systems.  
  4. Gas-generating systems.  
  Expandable systems.  
  Super porous hydro gel.  
  Mucoadhesive or bioadhesive systems.  
High-density Systems 
Sedimentation  has  been  employed  as  a  retention  mechanism  for 
pellets that are small enough to be retained in the rugae or folds of 
the stomach body near the pyloric region, which is the part of the 
organ with the lowest position in an upright posture. Dense pellets 
(approximately 3g/cm3) trapped in rugae also tend to withstand the 
peristaltic  movements  of  the  stomach  wall.  With  pellets,  the  GI 
transit  time  can  be  extended  from  an  average  of  5.8–25  hours, 
depending more on density than on diameter of the pellets, although 
many conflicting reports stating otherwise also abound in literature. 
Commonly  used  Excipients  are  barium  sulphate,  zinc  oxide, 
titanium  dioxide  and  iron  powder,  etc.  These  materials  increase 
density by up to 1.5–2.4 g/cm3. However, no successful high density 
system has made it to the market. 
1.  Large  Single-  unit  Dosage  Forms  -  these  dosage  forms  are 
larger  than  the  pyloric  opening  and  so  are  retained  in  the 
stomach.  There  are  some  drawbacks  associated  with  this 
approach.  Permanent  retention  of  rigid  large-sized  single-unit 
forms  can  cause  bowel  obstruction,  intestinal  adhesion  and 
gastroplasty  
2.  Floating systems can be based on the following: 
1.  Hydrodynamically  balanced  systems  (HBS)  –  incorporated 
buoyant materials enable the device to float;  
2.  Effervescent systems – gas-generating materials such as sodium 
bicarbonates  or  other  carbonate  salts  are  incorporated.  These 
materials  react  with  gastric  acid  and  produce  carbon  dioxide, 
which entraps in the colloidal matrix and allows them to float; 
3.  Low-density systems -- have a density lower than that of the 
gastric fluid so they are buoyant; 
4.  Bioadhesive or Mucoadhesive systems – these systems permit 
a  given  drug  delivery  system  (DDS)  to  be  incorporated  with 
bio/Mucoadhesive agents, enabling the device to adhere to the 
stomach  (or  other  GI)  walls,  thus  resisting  gastric  emptying. 
However, the mucus on the walls of the stomach is in a state of 
constant renewal, resulting in unpredictable adherence.
2 
Advantages Of Gastroretentive Drug Delivery System  
Gastro retentive drug delivery systems have numerous advantages 
listed below
3: 
1.  The principle of HBS can be used for any particular medicament 
or class of medicament. 
2.  The HBS formulations are not restricted to medicaments, which 
are  principally  absorbed  from  the  stomach.  Since  it  has  been 
found that these are equally efficacious with medicaments which 
are absorbed from the intestine e.g. Chlorpheniramine maleate. 
3.  The  HBS  are  advantageous  for  drugs  absorbed  through  the 
stomach e.g. ferrous salts and for drugs meant for local action in 
the stomach and treatment of peptic ulcer disease e.g. antacids. 
4.  The  efficacy  of  the  medicaments  administered  utilizing  the 
sustained  release  principle  of  HBS  has  been  found  to  be 
independent  of  the  site  of  absorption  of  the  particular 
medicaments. 
5.  Administration of a prolonged release floating dosage form tablet 
or capsule will result in dissolution of the drug in gastric fluid. 
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available  for  absorption  in  the  small  intestine.  It  is  therefore 
expected  that a  drug  will  be  fully  absorbed  from  the  floating 
dosage form if it remains in solution form even at alkaline pH of 
the intestine. 
6.  When there is vigorous intestinal movement and a short transit 
time as might occur in certain type of diarrhea, poor absorption is 
expected under such circumstances it may  be advantageous to 
keep the drug in floating condition in stomach to get a relatively 
better response. 
7.  Gastric retention will provide advantages such as the delivery of 
drugs  with narrow  absorption  windows  in  the  small  intestinal 
region. 
8.  Many  drugs  categorized  as  once-a-day  delivery  have  been 
demonstrated to have suboptimal absorption due to dependence 
on  the  transit  time  of  the  dosage  form,  making  traditional 
extended release development challenging. Therefore, a system 
designed for longer gastric retention will extend the time within 
which drug absorption can occur in the small intestine. 
9.  Certain types of drugs can benefit from using gastro retentive 
devices. These include: 
·  Drugs acting locally in the stomach; 
·  Drugs those are primarily absorbed in the stomach; 
·  Drugs those are poorly soluble at an alkaline pH; 
·  Drugs with a narrow window of absorption; 
·  Drugs absorbed rapidly from the GI tract; and 
·  Drugs those degrade in the colon.
3 
Disadvantages of gastro retentive drug delivery systems  
1.  There  are  certain  situations  where  gastric  retention  is  not 
desirable. Aspirin and nonsteroidal anti-inflammatory drugs are 
known to cause gastric lesions, and slow release of such drugs in 
the stomach is unwanted. 
2.  Thus, drugs that may irritate the stomach lining or are unstable in 
its  acidic  environment  should  not  be  formulated  in  gastro 
retentive systems. 
3.  Furthermore, other drugs, such as isosorbide dinitrate, that are 
absorbed equally  well throughout the GI tract will not benefit 
from incorporation into a gastric retention system.
4 
Applications of GRDDS 
 
Gastroretentive drug delivery  offers several applications for drugs 
having  poor  bioavailability  because  of  the  narrow  absorption 
window in the upper part of the gastrointestinal tract. It retains the 
dosage  form  at  the  site  of  absorption  and  thus  enhances  the 
bioavailability. These are summarized as follows
5, 6. 
Sustained Drug Delivery 
HBS systems can remain in the stomach for long periods and hence 
can release the drug over a prolonged period of time. The problem of 
short  gastric  residence  time  encountered  with  an  oral  CR 
formulation  hence  can  be  overcome  with  these  systems.  These 
systems have a bulk density of G1 as a result of which they can float 
on the gastric contents. These systems are relatively large in size and 
passing from the pyloric opening is prohibited. 
Site-Specific Drug Delivery 
These  systems  are  particularly  advantageous  for  drugs  that  are 
specifically absorbed from stomach or the proximal part of the small 
intestine, e.g., riboflavin and Furosemide. 
Absorption Enhancement 
Drugs  that  have  poor  bioavailability  because  of  site  specific 
absorption  from  the  upper  part  of  the  gastrointestinal  tract  are 
potential  candidates  to  be  formulated  as  floating  drug  delivery 
systems, thereby maximizing their absorption. GRDDS also serves 
as  an  excellent  drug  delivery  system  for  the  eradication  of 
Helicobacter pylori, which causes chronic gastritis and peptic ulcers. 
The treatment requires high drug concentrations to be maintained at 
the site of infection that is within the gastric mucosa. By virtue of its 
floating ability  these  dosage  forms  can  be  retained  in  the  gastric 
region for a prolonged period so that the drug can be targeted. 
An Overview of Gastroretentive Drug Delivery System Research 
Microspheres 
Shrivastava  A  et  al  prepared  cimetidine  loaded  microspheres  by 
solvent  evaporation  method  using  polymers  HPMC  &  EC  and 
reported  that  the  prepared  microspheres  exhibit  prolonged  drug 
release (~8 hrs ) & remained buoyant for 9-10 hrs. The mean particle 
size  decreased  at  higher  polymer  concentration.  In  vitro  studies 
demonstrated  diffusion  controlled  release  from 
microspheres
7.Hollow  microspheres  or  microballons  (MB)  of 
riboflavin  were  prepared  by  Sato  Y  et  al  using  emulsion  solvent 
diffusion method by dissolving enteric acrylic polymers in a mixture 
of  dichloromethane  and  ethanol.  The  pharmacokinetics  of  MB 
riboflavin  was  investigated  by  analysis  of  urinary  examination. 
Strong correlations were observed between the excretion half life, 
buoyancy,  riboflavin  release  from  the  MB  and  the  total  urinary 
excretion
8. 
Streubel A et al used polypropylene foam powder as porous carrier 
for  development  of  verapamil  HCL  loaded  microparticles  by  o/w 
solvent evaporation method. The encapsulation efficiency was high 
and almost independent of the microparticles loading. Good in vitro 
floating behavior was observed that release rate was increased with 
increasing drug loading and decreasing polymer amounts
9.Jain sk et 
al have developed and reported in vitro characterization of calcium 
silicate (CS) based floating microspheres of repaglinide by emulsion 
solvent  diffusion  technique  comprising  of  calcium  silicate  (CS), 
repaglinide and Eudragit S .The formulation demonstrated favorable 
in vitro floating and release characteristics and high  encapsulation 
efficiency
10.  Kawashima  et  al  described  Hollow  microspheres 
(microballons) consisting of Eudragit S an enteric polymer, loaded 
with drug in the outer shells, the ethanol rapidly partitioned into an 
external  aqueous  phase  and  the  polymer  precipitated  around 
methylene  chloride  droplets.  The  subsequent  evaporation  of  the 
entrapped  methylene  chloride  led  to  the  formation  of  internal 
cavities  within  the  microparticles
11.  Ali  J  et  al  prepared 
microspheres  for  celecoxib  to  enhance  its  bioavailability  by 
increasing  gastric  residence  time  using  four  different  polymers 
polyethylene oxide, Eudragit S, cellulose acetate, and  Eudragit RL 
by an emulsion-solvents (dichloromethane and ethanol) that differed 
in  the rate  of  diffusion  led  to  formation  of  a  hollow  core  in  the 
microspheres,  which  was  partially  responsible  for  the  floatation 
ability
12.Methylcellulose  and  chitosan  micro  pellets  loaded  with 
lansoprazole  have prepared by Muthusamy et al micro pellets had a 
lower  density  than  gastric  contents  and  exhibited  better 
encapsulation efficiencie
13. Heng P.W.S et al prepared the formative 
process  of  alginate  microspheres  using  emulsification  technique. 
The alginate microspheres were produced by cross linking alginate 
globules  dispersed  in  a  continuous  organic  phase  using  various 
calcium salts: calcium chloride, calcium acetate, and calcium lactate 
and  calcium  gluconate.  The  size,  shape,  drug  content  and  Ca
+2 
content of the microspheres were evaluated. The tack, viscosity and 
pH of the calcium salt solution and percentage of Ca
2+ partitioned 
into the organic phase were determined. Microscopic examination of 
the test emulsion at various stages of the emulsification process was 
also  carried  out
14.
  Synthesis  and  characterization  of  cross  linked 
chitosan microspheres containing a hydrophilic drug, hydroquinone 
were carried out. By Dini E. et al microspheres were prepared by the 
suspension cross linking method using glutaraldehyde as the cross 
linking agent of the polymer matrix. The effect of degree of cross 
linking, chitosan molecular weight concentration and the amount of 
encapsulated  drug  on  the  hydroquinone  release  kinetics  was 
extensively  investigated
15  Rokhade  A.P.  patel  and  et  al  prepared 
hollow  microspheres  of  cellulose  acetate  butyrate(CAB)  and 
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method. Repaglinide was successfully encapsulated into the floating 
microspheres
16. Hyuk sang yoo prepared biodegradable polymeric 
hollow  microspheres  by  double  oil  and  water  emulsion  using  the 
lipophilic surfactant, labrafil® M 1994 CS. Olive oil was emulsified 
in  biodegradable  polymer-dissolved  dichloromethane  mixed  with 
labrafil by vigorous sonication. This oil in oil emulsion was directly 
re-emulsified  in  0.1%  polyvinyl  alcohol  (PVA)  solution, 
subsequently  solidified  by  evaporating  dichloromethane. Olive  oil 
and labrafil were extracted from the microspheres by using hexane
17.
 
Yang  YC  et  al  prepared  and  evaluated  sustained  release  EC 
microspheres  containing  aspirin  by  emulsification  solvent 
evaporation  technique.  The  release  rate  follows  1
st  order  kinetics 
during  first  12hr,suggesting  a  monolithic  system  with  aspirin 
uniformly  distributed  in  the  microcapsules,  recovered  weight  and 
loading affiance but decreasing the release rate
18.
 Saravan M, et al 
prepared EC microspheres loaded  with ibuprofen  with or without 
polystyrene,  which  was  used  to  retard  drug  release  from  the 
microspheres  by  solvent  evaporation  technique. The  microspheres 
show 80-92% entrapment depending upon drug polymer ratio. High 
concentration  was  obtained  in  higuchi  and  korsmeyer-Peppas 
models. Drug release was found to be diffusion controlled
19.
  Cheu 
JS et al prepared a controlled release micro particulate dosage form 
for acyclovir with EC by oil in water solvent evaporation technique. 
A 2
3 full factorial design was applied to study effect of viscosity of 
polymer, drug polymer ratio and polymer concentration on the drug 
encapsulation  and  dissolution  characteristics.  A  faster  release  of 
drug  was  observed  when  a  high  viscosity  polymer  was  used
20.
 
Fernandez-Urrusuno R, et al prepared controlled release formulation 
of alachlor in EC by solvent evaporation technique. Results showed 
that microspheres retard the release of alachlor in different degrees. 
The  pesticide  alachlor-polymer  ratio  and  particle  size  were 
important  factors  for  determining  that  alachlor  release  .EC 
microspheres may prove useful for prolonged release of alachlor
21. 
Mohan Kamila M, et al  have developed a multiunit floating drug 
delivery system of rosiglitazone maleate by encapsulating the drug 
into  Eudragit  RS100  through  non  aqueous  emulsification/solvent 
evaporation method. The results showed that floating microspheres 
could  be  successfully  prepared  with  good  yields  (69-75%),  high 
entrapment  (78-97%), narrow  size  distribution, and  desired  target 
release with the help of statistical design of experiments from very 
small  number  of  formulations.  In  vivo  evaluation  in  albino  rats 
suggested  that  floating  microspheres  of  rosiglitazone  could  be  a 
promising  approach  for  better  glycemic  control
22.
  Sato  Y  et  al 
developed a dosage form capable of floating in the stomach. Hollow 
microspheres  prepared  by  the  emulsion  solvent  diffusion  method 
using enteric acrylic polymers with riboflavin dichloromethane and 
ethanol. The optimum loading amount of riboflavin micro balloon 
was found to impart ideal floatable properties to the microballoons
23. 
Kalmel  AH  et  al  prepared  floating  microparticles  by  emulsion-
solvent diffusion technique. Four different ratios of Eudragit S 100 
(ES)  with  Eudragit  RL  (ERL)  were  used  to  form  the  floating 
microparticles.  The  drug  retained  in  the  floating  microparticles 
decreased  with  the  increase  in  ERL  content.  All  floating 
microparticles  showed  good  flow  properties  and  packability
24.
 
Sharma  S  et  al  developed  multiperticulate  floating-pulsatile  drug 
delivery  system  using  porous  calcium  silicate  (fluorite  RE)  and 
sodium  alginate,  for  time  and  size  specific  drug  release  of 
meloxicam  developed  formulation  was  evaluated
25.  Liu  Z  et  al 
prepared  amoxicillin  Mucoadhesive  microspheres  (amo-ad-ms) 
using  ethyl  cellulose  (ES),  as  matrix  and  carbapol  934P  as 
Mucoadhesive polymer for the potential use of gastric and duodenal 
ulcers. In vitro and in vivo Mucoadhesive test showed that amo-ad-
ms  adhered  more  strongly  to  the  gastric  than  nonadhesive 
amoxicillin  microspheres  amo-Ec-ms  did.  The  result  showed  that 
amo-ad-ms had a better clearance effect than amoxicillin powder did 
in the rats
26.  
Microcapsule 
Moldenhaver  et  al  relate  the  solubility  properties  of  EC 
microcapsule,  different  microcapsule  systems  was  prepared  using 
various  solvent  and  non  solvents.  Results  indicated  that 
microcapsules  prepared  using  solvent  mixtures  added  a  solubility 
parameter
27. Jones DS et al observed the effects  of some process 
variables  on  the  microcapsule  of  propranolol  HCl  by  solvent 
evaporation  method  with  EC  using  a  factorial  design.  Minimum 
percent  w/w  entrapments  of  propranolol  when  external  aqueous 
phase  contains  1.5%  w/v  gelatin  at  PH  6.00  and  maximum 
entrapment  of  the  drug  occurred  when  the  external  phase  was 
composed of 0.5% w/v gelatin at the PH 9.00. Gelatin concentration 
and  pH  significantly  affects  the  entrapment
28.Ertan  Gand  et  al 
formulated dual Nitrofurantoin and amoxicillin microcapsules with 
oxolamine  citrate,  EC  and  gelatin.  Nitrofurantoin  release  from 
microcapsules was lower. The dissolution rate results of amoxicillin: 
gelatin with carboxy methyl cellulose and dual EC microcapsules 
showed  a  good  sustained  action
29.  Ali  J  et  al  prepared 
hydrodynamically balanced system (HBS) for metformin as a single 
floating  capsule  with  HMPC  K4M  and  EC.  The  formulation 
remained  buoyant  during  5  hr  study  in  rabbits.  The  comparative 
pharmacokinetic  studies  were  performed  by  administration  of  the 
optimized  HBS  and  immediate  release  capsules  both  with 
radiolabelled  metformin,  using  gamma  counter.  There  was  an 
increase  in  AUC  in  optimized  HBS  capsules  of  metformin  when 
compared  with  immediate  release  metformin
30.  Dennis  A  et  al 
proposed a loose powder filled capsule that is Buoyant so that it will 
float on a gastric juices and thereby improved drug availability
31. 
Gibaly Fist prepared floating microcapsules containing melatonin by 
ionic interaction and a negatively charged surfactant, sodium dioctyl 
sulfosuccinate  (DOS).  The  characteristics  of  the  Floating 
microcapsules generated compared with conventional non floating 
microspheres  manufactured  from  chitosan  and  sodium 
tripolyphosphate  (TPP)  were  also  investigated.  The  dissolution 
profiles of most microcapsules showed near zero order kinetics in 
simulated gastric fluid (S.G.F: pH i.2) moreover, release of the drug 
from these microspheres was greatly retarded with release lasting for 
several hr. (t50% (S.G.F):1.75-6.7 hr, depending on the processing 
factor), compared with the Non Floating microspheres where drug 
release was almost instant. Most of the hollow spheres developed 
tended to float over simulated fluids for more than 12 hr 
32. 
Floating gel beads 
Tang Y et al synthesized a multi-unit floating gel bead with calcium 
alginate,  sunflower  oil  and  a  drug  of  interest  through  an 
emulsification/ gelatin process. The alginate beads with oil addition 
were able to continuously float over the medium for 24 hr. Under the 
constant agitation while the non–oily beads could not. Three kind of 
drug  with  different  hydrophilicities  ibuprofen,  niaciamide  and 
metaclopromide  HCl  were  tested  in  the  study
33.  Badve  S  et  al 
developed  hollow  /porous  calcium  pactinate  beads  for  floating–
pulsatile  release  of  diclofenac  sodium  intended  for 
chronopharmacotherapy. The floating beads obtained were porous 
(34% porosity), hollow with bulk density ≤1 and had FT50% of the 
14-24  hr.  In  vivo  studies  by  ¥  -scintigraphy  determined  on  the 
rabbits  showed  the  gastro  retention  of  beads  up  to  5  hr
34. 
Sriamornsak  P,  et  al  developed  emulsion  gel  beads  of  calcium 
pectinate  capable  of  floating  in  the  gastric  condition  using  an 
emulsion  gelation  method  and  their  release  properties  were 
investigated. The metronidazole-loaded emulsion gel was found to 
float  on  the  simulated  gastric  fluid.  The  additives  (PEG  10000, 
glyceryl  monostearate  and  Eudragit  L) had  a  slight  in  significant 
effect on the drug release. The result suggest that emulsion gel beads 
are suitable as a carrier for intra gastric floating drug delivery system Lahoti S.R et al. IRJP 2011, 2 (11), 50-57 
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and that their release behavior could be modified by hardening with 
glutaraldehyde  or  by  coating  with  Eudragit  L
35.  Mutara  Y  et  al 
prepared  two  types  of  alginate  beads  capable  of  floating  in  the 
gastric cavity. The first alginate gel bead containing vegetable oil 
(ALGO),  releases  model  drug  metronidazole  which  is  inversely 
proportional to the percentage of oil. The second alginate gel bead 
containing chitosan (ALCS) is a dried gel. The drug release profile 
was not affected by the kind of chitosan in the matrix when ALCS 
containing metronidazole was administered orally to guinea pig, it 
float on the gastric juice and release the drug in the stomach36.Ishak 
R  et  al  prepared a metronidazole  loaded  chitosan-treated alginate 
beads  by  ion  tropic  gelation  method.  A  3
2  factorial  designed 
experiment  was  used  in  which  the  three  viscosity  imparting 
polymers namely methyl cellulose, carbapol 934P and ĸ-carragenan 
and the clearance rate was studied
37. Alaa Eldeen B. Yassin, Ibrahim 
A design a new extended release gastro retentive multi particulate 
delivery system for verapamil by incorporation into hydro gel beads 
made of chitosan. The beads were formed by dropping solutions of 
VP and chitosan in a solution of tripolyphosphate using a syringe 
pump  with adjustable  constant rate. The  formed  beads  were  then 
further  cross  linked  using  glutaraldehyde  and  the  excess 
glutaraldehyde was then washed
38. Fell.J.T et al prepared floating 
alginate beads incorporating amoxicillin. The beads where produced 
by  drop  wise  addition  of  alginate  into  calcium  chloride  solution, 
followed  by  removal  of  gel  beads  and  freeze-drying.  The  beads 
containing the dissolved drug remained buoyant for 20 hours and 
high drug-loading levels were achieved
39.
 
Floating matrix tablets 
Strubing S et al have prepared floating kollidonn SR matrix tablets 
containing  propanolol  HCL.  The  tablet  floats  immediately  and 
continued  for  24  hr.  They  found  that  the  floating  strength  was 
related  to  kollidon  SR  level.  Floating  characteristics  for  sample 
improved with a high polymer/drug ratio. Swelling characteristics of 
the  tablets  were  also  related  to  the  polymer  content  but  it  was 
marginal 
40.Ozedemir et al developed floating bilayer tablets with 
controlled release for furosamide. They have design bilayer dosage 
form in which one layer contained HPMC 4000, HPMC 100 and 
carboxy  methyl  cellulose  and  the  second  layer  contained  the 
effervescent  mixture  of  sodium  bicarbonate  and  citric  acid.  The 
radiographic studies showed that floating tablets were retained in the 
stomach for 6 hr and blood analysis showed that bioavailability of 
these tablets was 1.8 times more that of the conventional tablets
41 A 
floating  multi-layer  coated  tablets  was  prepared  by  Srisagul 
Sungthongjeen et al which consist of drug containing core tablets 
coated  with  a  protective  layer  and  a  polymeric  membrane.    And 
found that polymeric film with the high flexibility (Eudragit RL30D) 
had  the  high  capability  to  entrap  the  generated  gas  CO2  and 
subsequent good floating properties. The floating properties and the 
drug release from the floating tablets were dependent on the core 
preparation method, the amount of gas forming agent and the level 
of gas entrapped membrane
42. Streubel et al’s  single unit floating 
controlled drug delivery systems consisting of polypropylene foam 
powder, matrix foaming polymer, drug and filler. They studied the 
different  types  of  matrix  foaming  polymers  like  HPMC, 
polyacrylates, sodium alginate, corn starch, carragenan, guar gum 
and gum Arabic. It was found that release rate could effectively be 
modified  by  varying  the  matrix  foaming  polymer  and  the  foam 
polymer  ratio,  initial  drug  loading,  tablet  geometry,  the  types  of 
matrix foaming polymer, the use of polymer blends and the addition 
of  water  soluble  or  water  insoluble  fillers  (such  as  lactose  or 
microcrystalline  cellulose)
  43.Dave  B  et  al  had  prepared  a  gastro 
retentive drug delivery system of ranitidine HCL. They evaluated 
guar gum, xanthan gum, and HPMC for gel-forming properties and 
sodium bicarbonate as a gas generating agent. Also found that the 
addition  of  stearic  acid  reduces  the  drug  dissolution  due  to  its 
hydrophobic  nature.  Hence  concluded  that  the  proper  balance 
between a release rate enhancer and the release rate retardant can 
produce a drug dissolution profile similar to a theoretical dissolution 
profile
44.  Sun  woo  jang  et  al has  developed  an  effective  floating 
matrix system of a new synthetic falconoid derivative i.e. (DA-6034) 
for the treatment of gastritis. The therapeutic limitation of DA-6034 
caused by its solubility in low acidic conditions was overcome by 
using the effervescent floating matrix system, which was designed to 
cause tablet to float   in the gastric fluid. They concluded that the 
release  of  DA-6034  from  the  tablet  in  the  acidic  medium  was 
significantly improved by this technique, which is attributed to the 
effect  of  solubilizers  and  the  alkalizing  agent  such  as  sodium 
bicarbonate  used  as  gas  generating  agent
45.  Ziyaur  rehman  et  al 
prepared  a  bilayer  floating  tablet  for  captopril  using  direct 
compression technology with one layer as floating and other as a 
release  layer.  The  floating  layer  contained  HPMC  K  grade  and 
effervescent mixture of sodium bicarbonate and citric acid. While 
the release layer contained captopril and various polymers such as 
HPMC K15 M, PVP K30 and carbapol 934P. Excellent release was 
observe
46. Shrivastava et al have developed floating matrix tablets of 
atanolol. Tablet were prepared using polymer such as HPMC K15M, 
HPMC K4M, guar gum and sodium carboxy methyl cellulose alone 
or in combination. They found that the tablet containing guar gum 
and  sodium  carboxy  methyl  cellulose  shows  the  greater  swelling 
indices and the tablet exhibit controlled and prolonged drug release 
and floats effectively in the dissolution medium
47.Xiaoquiang Xu et 
al have worked on Floating matrix dosage form for phenoporlamine 
HCL based on the gas forming agent. HPMC K4M and carbapol 971 
NF  were  used  in  the  formulation.  They  float  over  6  hrs  and  the 
dissolution profile shows the non fickian diffusion. Also found that 
the carbapol 971 NF was capable of sustained release and increase in 
the  bioavailability
48.  Sigmund  W  et  al  have  described  a  gamma 
scintigraphy  evaluation  of  the  fate  of  micro  crystalline  chitosan 
granules in the fasted human stomach
49. Talwar et al developed once 
a  daily  formulation  for  ciprofloxacin.  The  formulation  was 
composed of ciprofloxacin, sodium alginate, xanthan gum, sodium 
bicarbonate and crosspovidone. The viscolysing agent and the gel 
formatting polymer formed a hydrated mixture that entrapped the 
gas, causing the tablet to float and be retained in the stomach or 
upper  part  of  small  intestine.  The  hydrated  gel  matrix  created  a 
tortuous diffusion path for the drug, resulting in sustained release of 
the drug
50 Penners et al developed an expandable tablet containing 
mixtures of polyvinyl lactones and polyacrylates that swell rapidly 
in the aqueous environment and thus reside in the stomach over an 
extended period of time in addition to this, gas forming agents were 
also incorporate. The gas formed decease the system and thus the 
system tend to float on the gastric content
51 Yang et al developed 
new  strategy  for  the  triple  drug  treatment  (tetracycline, 
metronidazole and bismuth salt) of Helicobacter pylori associated 
with  gastric  ulcer.  They  have  designed  sellable  asymmetric  triple 
layer tablet with floating ability which prolongs the gastric residence 
time of the drug regimen of Helicobacter pylori. Hydroxy propyl 
methyl cellulose and poly (ethylene oxide) were use as major rate 
controlling  polymeric  Excipients.  Tetracycline  and  metronidazole 
were  incorporated  in  the  core  layer  of  the  triple-layer  matrix  for 
controlled delivery,  while the bismuth salt included in one of the 
outer  layers  for  the  instant  release.  The  resultant  drug  delivery 
system has the potential to increase the efficacy of the therapy and 
the  patient  compliance
52  .A  multi-unit  levodopa  sustained  release 
floating  dosage  forms  was  developed  by  Goole  et  al.  This 
minitablets (MT) were prepared by melt granulation and subsequent 
compression. From the dissolution profile of levodopa at different 
pH values it was found that dissolution profiles depend more on the 
prolonged  release  ability  of  Methacol  K15M  than  on  the  pH 
dependent solubility of levodopa
53. Talukedar et al have evaluated Lahoti S.R et al. IRJP 2011, 2 (11), 50-57 
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xanthan  gum  as  the  potential  Excipients  for  the  oral  controlled-
release matrix tablet. Investigate the controlled release properties of 
xanthan  gum.  Indomethacin and the  sodium  salt  of  Indomethacin 
were  selected  as  a  model  drug.  The  performance  of  XG  was 
compared  with  marketed  controlled  release  products  of 
Indomethacin.  It  was  found  that  the  drug  released  from  the  test 
products reached the minimum effective concentration earlier and 
remained longer within the therapeutic range
54. Viral patel et al have 
developed an intra gastric drug delivery system for cefuroxime axetil 
and evaluated contribution of HPMC K4M/K100LV ratio (polymer 
bled) and sodium lauryl sulfate (SLS) on drug release. It was found 
that polymer blend and SLS significantly affected the time required 
for 50% of drug release and percent release drug release at 12 hr
55. 
Maria Elena et al had studied the influence of the HPMC viscosity 
grade  and  release  profile  of  metronidazole  matrix  tablet.  The 
effluence was evaluated at viscosity grades of 15, 860, 5000, 20000 
and 30000 CP and particle sizes of 163, 335 and 505 pm. The results 
showed a linear relationship between the inverse of release rate and 
the viscosity grade of HPMC. An increasing burst effect occurred 
with  increase  viscosity  grades  and  increasing  particle  sizes  of 
HMPC
56.Dasharath patel et al have prepared carbamazepine floating 
tablets  by  melt  granulation technique  using  beeswax,  HPMC, EC 
were used as matrix foaming agent while gas generating and floating 
enhancer. The results of multiple regression analysis indicated that 
low levels of HPMC and EC and a high level of sodium bicarbonate 
should be used to manufacture the tablet formulation with desired in 
vitro  floating  time  and  dissolution
57.
  Sasa  Baumgartner  et  al 
developed the floating matrix tablets, which after oral administration 
are designed to prolong the gastric residence time, increasing the 
drug bioavailability and diminish the side effects of irritating drugs. 
Tablets  containing  HPMC,  drug  and  different  additives  were 
compressed. The investigation showed that tablet composition and 
tablet strength have greater influence on the floating properties and 
the drug release. 
58Quan liu et al had developed Zero-order delivery 
of a highly soluble, low dose drug alfazosin HCL gastro-retentive 
system. Two system containing polyethylene oxide (PEO), HPMC, 
sodium bicarbonate, citric acid and polyvinyl pyrrolidone were dry 
blended  and  compressed  into  triple  layer  and  bi-layer  composite 
matrices. Both system proved to be effective in providing prolonged 
floatation, zero –order release. They suggested that the kinetics of 
drug  release,  swelling,  erosion  and  dynamics  of  textural  changes 
during  dissolution  for  developing  gastro-retentive  drug  delivery 
system that has potential to enhance bioavailability and site-specific 
delivery  of  the  proximal  small  intestine
59.Muralidher  nama  et  al 
have developed the Hydrodynamically balanced delivery system of 
clarithromycin which has the ability to prolong the gastric residence 
time with desired in vitro release profile for the localized action in 
the stomach. The tablet was prepared by wet granulation technique. 
In vivo radiographic studies were also performed with the barium 
sulphate  loaded  formulation.  It  was  found  that  the  formulation 
containing 66.2% Clarithromycin 12%, HPMC K4M, polymer, 8% 
sodium bicarbonate had floating lag time of 12 hr and the in vitro 
release  profile  very  near  to  the  desired  release
60.  Korgel  I,  and 
bodmeier  R  developed  a  floating  and  a  pulsatile  drug  delivery 
system based on the resevior system consisting of drug containing 
effervescent  core  and  a  polymeric  coating.  Eudragit  RL:  acetyl 
tributyl citrate was selected as to initiate the effervescent reaction 
and floating process. Ethyl cellulose: dibutyl sebacate was used for 
formulation  of  weak  semi  permiable  film  they  found  that,  the 
polymeric  coating  did  not  retard  the  drug  release  but  a  polymer 
(cellulose acetate or hydroxy propyl methyl cellulose) added to the 
core  controlled  the  drug  release.  A  quick  releasing  core  was 
formulated in order to obtain a rapid drug release after the rupture of 
polymer  coating
61.  A  floating  matrix  tablet  was  developed  by 
Baumgartner et al which incorporate a high dose of freely soluble 
drug.  The  formulation  containing  54.7%  of  drug,  HPMC  K4M, 
Avicel pH 101, and a gas generating agent gave the best results. It 
took  30  second  to  become  buoyant.  In  vivo  experiment  with  the 
fasted state beagledoge revealed prolonged gastric residence time. 
The results showed that the mean gastric residence time of the tablet 
was 240 ±60 minutes in dogs
62. Mousni el al prepared an oral drug 
delivery of the anti-psychotic agent carbamazepine facilited by non-
disintigrating floating dosage form. The polymer used was HPMC, 
guar gum, carbapol and NaHCO3 as a gas generating agent. It was 
observed that the carbamazepine release form floating dosage form 
was uniform followed a zero-order release. The devices containing 
higher portion of HPMC ( high viscosity ) show the slower release 
and  maintain  the  integrity  of  device  as  guar  gum  and  NaHCO3 
causes the tablet to float for required  time
63. Chaudhari pravin et al 
have  developed  a  bilayer  floating  tablet  of  tizanidine  HCL  using 
direct compression technique. HPMC K-grade, NaHCO3 and starch 
1500 form the floating layer. The release layer contains the drug and 
various polymers such as HPMC K15 M, gelucire 43/07 and xanthan 
gum  in  combination  with  HPMC  K15  M
64.  Nagalakshmi,  Abdul 
Hasan  Sathali  developed  a  hydrodynamically  balanced  system  of 
Pioglitazone  hydrochloride  (HCl),  by  non-effervescent  and 
effervescent techniques. Various grades of polymers (e.g. HPMC K-
100M, HPMC K-4M, HPMC K-30, HPMC K-15, SCMC and MC) 
were used alone and in combination. Sodium bicarbonate (NaHCO3) 
was used as a gas generating agent in effervescent technique. From 
the studies, it was found that 60 per cent of polymer concentration 
and 20mg of NaHCO3 provided good tablet floating behavior and 
also the possible shortest lag time was achieved
65.Katayama.H. et al 
developed a sustained release (SR) liquid preparation of Ampicillin 
containing sodium alginate, which spreads out and aids in adhering 
to  the  gastric  mucosal  surface.  Thus,  the  drug  is  continuously 
released in the gastric region 
66.
 
In situ gel 
Attwood D. et al evaluated theophylline gel formed in situ following 
oral administration of 1% (w/v) aqueous solution of gellan to rats 
and  rabbits  as  sustained  release  vehicles.  Formulation  complex 
contain calcium ions which leads to gelation in acidic environment 
and sustain the release. Bioavailability was increased 4-5 folds in 
rats  and  3  folds  in  rabbits  as  compare  to  commercial  oral 
formulation
67. Attwood D. et al evaluated theophylline gel formed in 
situ following oral administration of 1-2% (w/v) aqueous solution of 
sodium alginate to rats as sustained release vehicles. Formulation 
complex  contain  calcium  ions  which  leads  to  gelation  in  acidic 
environment and sustain the release. Bioavailability was increased 
1.3-2  folds  in  rats  compared  with  that  from  a  proprietary  oral 
sustained  release  formulation  containing  an  identical  drug 
formulation
68. Attwood D. et al evaluated potential for oral sustained 
delivery  of  paracetamol  of  2  formulations  with  in  situ  gelling 
properties.  Oral  administration  of  Formulation  complex  of  gellan 
gum 1%  (w/v) or sodium alginate 1.5% w/v contain calcium ions 
which  leads  to  gelation  in  acidic  environment  and  sustain  the 
release. Bioavailability of paracetamol from the gel formed in situ in 
stomach  of  rabbits  following  oral  administration  of  the  liquid 
formulation was similar to that of commercial available sustention 
containing  dose  of  paracetamol
69.  Attwood  D.  et  al  examine  the 
influence  of  variation  of  gastric  pH  over  the  range  1-3  on  the 
gelation  of  liquid  formulations  of  pectin  and  on  in  vitro  in  vivo 
release of paracetamol and ambroxol from resultant gels of pectin 
using gastric acidity controlled rabbits. The bioavailability of these 
drug  where  not  significantly  different  when  released  from  gel 
formed at the 2 different when released from gels formed at the 2 
different limits suggesting that normal variation of gastric acidity in 
the fasting state will have no effects on the bioavailability of these 
drugs when delivered using this vehicle
70. Allhaque F. et al studied 
the  ability  of  gellan to  form  gel  in the  presence  of  calcium  ions Lahoti S.R et al. IRJP 2011, 2 (11), 50-57 
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enable to form gel in presence of calcium ions unable to prepare 
capsule by gelation of this polysaccharide around a core containing 
starch, calcium chloride and a model drug. Released was studied in 
vivo  from  dried  capsule  from  different  environmental  condition 
(distill  water,  pH  2  and  8)  the  effect  of  presence  of  increasing 
amount of drug in the formulation where investigated. The behavior 
of gellan capsules was compared with that of beads prepared with 
the  same  polysaccharide  containing  different  additives.  Result 
obtained  indicated  that  gellan  is  suitable  for  formulating  suitable 
capsules and that solvent uptake the dried capsule is more likely the 
main  factor  capable  of  affecting  the  rate  of  delivery  the  tested 
preparations
71.
  Floating  in  situ  gel  system  of  clarithromycin  was 
prepared  by  B.  Mishra  and  Rajinikanth  P.S.  using  varying 
concentration of gellan as gelling polymer in de-ionized water to 
which varying concretion of drug and surfactant was dispersed and 
carbohydrate  as  floating  agent
72.  Intra  gastric  floating  in  situ  gel 
system of amoxicillin for the treatment of peptic ulcer caused by H. 
pylore containing varying concentration of gellan as gelling polymer 
in de-ionized water to which varying concretion of drug and sodium 
citrate    was  dispersed  and  calcium  carbohydrate  as  gas  forming 
agent  was  prepared  by  B.  Mishra  et  al.  the  in  vivo  H.  pylore 
clearance  efficacy  of  prepared  amoxicillin  floating  in  situ  gel  in 
reference  to  amoxicillin  suspension  followed  by  repeated  oral 
administration  of  H.  pylore  infected  Mongolian  gerbils  was 
examined  by  polymerase  chain  reaction  technique  and  by  a 
microbial culture method0
73.  Dettmar P. W. et al. tested the in vitro 
effectiveness of range of liquid product in raft that where cohesive, 
buoyant, voluminous, resistance to reflux durable under conditions 
of movement (resilient). The product tested has wide range of acid 
neutralizing capacity
74. Doijiad R. C. et al described the formulation 
and  evaluation  of  an  ophthalmic  delivery  system  of  gatifloxacin, 
based on concept of ion activation system. Sodium alginate was used 
as  a  gelling  agent  in  combination  with  HPMC  which  acted  as 
viscosity enhancing agent, formulation provided sustain release of 
drug over an 8 hour period
75. Juming Tang et al investigated the 
influence of divalent (Ca
+ and Mg
+) and monovalent (Na
+ and K
+) 
cations on the failure stress and strain in the gel formed with gellan 
polymer
76.  Katayama  et  al  reported  a  liquid  sustained  release 
formulation containing sodium alginate intended for the eradication 
of H pylore in which in situ gelling was achieved by the separating 
oral  administration  of  a  solution  of  calcium  salt  immediately 
following  that  of  sodium  alginate  solution
77.  Miyazaki  S.  et  al 
assessed 3 liquid formulations with in situ gelling properties for oral 
delivery of cimetidine. The formulations were dilute solutions of: (a) 
enzyme degraded xyloglucan, which forms thermally reversible gel 
on warming to body temperature; (b) gellan gum and; (c) sodium 
alginate containing complexed ions that forms gel when these ions 
are released in acidic environment of the stomach. Plasma level of 
cimitidine  after  oral  administration  to  rabbits  of  each  of  the 
formulation where compared with those of the formulations where 
compared with those resulting from administration of a commercial 
cimetidine/alginate  with  an  identical  drug  loading
78.  A  patent 
assigned to Reckitt and Colman products described a raft forming 
formulation using triclosan. The drug was mixed with alginic acid, 
sodium  bicarbonate,  calcium  carbonate  and  manitol.  The  mixture 
was granulated and citric acid was added to the granules and then 
packed in sachets or compressed to formed tablets. Bicarbonate and 
carbonate  salts  produce  effervescence,  which  aerated  the  raft 
structure  formed  by  alginates,  causing  it to  float
79.Shah D.P.  and 
Jain  G.K.  modified  gellan  gum  using  microwave  technology  and 
sowed it to be used as Excipients in tablet formulation. Result of this 
study show that modified gellan gum can be used as a disintegrant in 
tablet formulation. Only physical modification was carried out in the 
microwave oven. Modified gellan gum showed excellence swelling 
capacity,  flow  property  and  compressibility 
80.Yuguchi  Y.  et  al 
studied the effect of potassium ions on the structural characteristics 
of  gellan gum  gel. The  cross  linking  domain  structure in  various 
concentrations  of  K
+  salts  was  observed  by  small  angle  X-ray 
scattering. The result was analyzed by means of molecular models of 
associated  double  helices.  It  found  that  the  gelation  yielded  the 
mono-layer flat particles concentrated by side by side aggregation of 
double helices at lower salt concentration and then they grew up to 
the  multilayer  aggregate  by  further  addition  of  salt
81.  Zatz  and 
Woodfords  developed  a  suspension  formulation  of  theophylline 
which contained sodium alginate and which formed a gel when in 
contacted with stimulated gastric fluid 
82. 
CONCLUSION   
The literature searched during the review of the topic reviled that 
gastro retentive approach is best alternative for the formulation of 
drug with Narrow therapeutic window to increase the bioavailability. 
In the ongoing research work in the field of gastro retentive drug 
delivery  various  novel  approaches  and  techniques  have  been 
successfully  tried  by  various  researchers.  At  present  many 
formulations based on these approaches have find their way to the 
market and used by the physicians for treatment of patients.    
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